Role of complement and perspectives for intervention in ischemia-reperfusion damage

References

• Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058–66.
   PubMed Web of Science ®Google Scholar
• Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140–4.
   PubMed Web of Science ®Google Scholar
• Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol. 2004;555:589–606.
   PubMed Web of Science ®Google Scholar
• Hess ML, Manson NH. Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. J Mol Cell Cardiol. 1984;16:969–85.
   PubMed Web of Science ®Google Scholar
• Ambrosio G, Becker LC, Hutchins GM, Weisman HF, Weisfeldt ML. Reduction in experimental infarct size by recombinant human superoxide dismutase: insights into the pathophysiology of reperfusion injury. Circulation. 1986; 74:1424–33.
   PubMed Web of Science ®Google Scholar
• Pollak R, Andrisevic JH, Maddux MS, Gruber SA, Paller MS. A randomized double-blind trial of the use of human recombinant superoxide dismutase in renal transplantation. Transplantation. 1993;55:57–60.
   PubMed Web of Science ®Google Scholar
• Svendsen JH, Bjerrum PJ. Effects of exogenous oxygen derived free radicals on myocardial capillary permeability, vascular tone, and incidence of ventricular arrhythmias in the canine heart. Cardiovasc Res. 1992;26:1181–8.
   Google Scholar
• Kubes P, Jutila M, Payne D. Therapeutic potential of inhibiting leukocyte rolling in ischemia/reperfusion. J Clin Invest. 1995;95:2510–9.
   PubMed Web of Science ®Google Scholar
• Kawamura T, Kadosaki M, Nara N, Wei J, Endo S, Inada K. Nicorandil attenuates NF-kappaB activation, adhesion molecule expression, and cytokine production in patients with coronary artery bypass surgery. Shock. 2005;24: 103–8.
   PubMedGoogle Scholar
• Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454: 345–59.
   PubMed Web of Science ®Google Scholar
• Mulivor AW, Lipowsky HH. Inflammation and ischemia induced shedding of the venular glycocalyx. Am J Physiol Heart Circ Physiol. 2004;286:H1672–80.
   PubMed Web of Science ®Google Scholar
• Platts SH, Linden J, Duling BR. Rapid modification of the glycocalyx caused by ischemia-reperfusion is inhibited by adenosine A2A receptor activation. Am J Physiol Heart Circ Physiol. 2003;284:H2360–7.
   PubMedGoogle Scholar
• Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, . C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97–103.
   PubMed Web of Science ®Google Scholar
• Krijnen PA, Ciurana C, Cramer T, Hazes T, Meijer CJ, Visser CA, . IgM colocalises with complement and C reactive protein in infarcted human myocardium. J Clin Pathol. 2005;58:382–8.
   Google Scholar
• De Simoni MG, Rossi E, Storini C, Pizzimenti S, Echart C, Bergamaschini L. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am J Pathol. 2004;164:1857–63.
   PubMed Web of Science ®Google Scholar
• Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, . Role for the alternative complement pathway in ischemia/reperfusion injury. Am J Pathol. 2003;162:449–55.
   PubMed Web of Science ®Google Scholar
• Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol. 2003;170:1517–23.
   PubMed Web of Science ®Google Scholar
• Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation. 2001;104:1413–8.
   PubMed Web of Science ®Google Scholar
• Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, . Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol. 2005;174:6373–80.
   PubMed Web of Science ®Google Scholar
• Busche MN, Pavlov V, Takahashi K, Stahl GL. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol. 2009;297:H1853–9.
   Google Scholar
• Castellano G, Melchiorre R, Loverre A, Ditonno P, Montinaro V, Rossini M, . Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010;176:1648–59.
   PubMed Web of Science ®Google Scholar
• Trendelenburg M, Theroux P, Stebbins A, Granger C, Armstrong P, Pfisterer M. Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J. 2010;31:1181–7.
   PubMedGoogle Scholar
• Zhang M, Takahashi K, Alicot EM, Vorup-Jensen T, Kessler B, Thiel S, . Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol. 2006;177:4727–34.
   PubMed Web of Science ®Google Scholar
• Zhang M, Alicot EM, Carroll MC. Human natural IgM can induce ischemia/reperfusion injury in a murine intestinal model. Mol Immunol. 2008;45:4036–9.
   Google Scholar
• Fleming SD, Egan RP, Chai C, Girardi G, Holers VM, Salmon J, . Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion-induced injury in complement receptor 2/complement receptor 1-deficient mice. J Immunol. 2004;173:7055–61.
   PubMedGoogle Scholar
• Kulik L, Fleming SD, Moratz C, Reuter JW, Novikov A, Chen K, . Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol. 2009;182:5363–73.
   Google Scholar
• Keith MP, Moratz C, Egan R, Zacharia A, Greidinger EL, Hoffman RW, . Anti-ribonucleoprotein antibodies mediate enhanced lung injury following mesenteric ischemia/reperfusion in Rag-1(-/-) mice. Autoimmunity. 2007;40:208–16.
   PubMed Web of Science ®Google Scholar
• Rossen RD, Swain JL, Michael LH, Weakley S, Giannini E, Entman ML. Selective accumulation of the first component of complement and leukocytes in ischemic canine heart muscle. A possible initiator of an extra myocardial mechanism of ischemic injury. Circ Res. 1985;57:119–30.
   PubMed Web of Science ®Google Scholar
• Kagiyama A, Savage HE, Michael LH, Hanson G, Entman ML, Rossen RD. Molecular basis of complement activation in ischemic myocardium: identification of specific molecules of mitochondrial origin that bind human C1q and fix complement. Circ Res. 1989;64:607–15.
   PubMed Web of Science ®Google Scholar
• De Vries B, Kohl J, Leclercq WK, Wolfs TG, van Bijnen AA, Heeringa P, . Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol. 2003;170:3883–9.
   PubMed Web of Science ®Google Scholar
• Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, . C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94: 1147–55.
   PubMed Web of Science ®Google Scholar
• Rinder CS, Rinder HM, Smith MJ, Tracey JB, Fitch J, Li L, . Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. J Thorac Cardiovasc Surg. 1999;118:460–6.
   PubMed Web of Science ®Google Scholar
• Collard CD, Agah A, Reenstra W, Buras J, Stahl GL. Endothelial nuclear factor-kappaB translocation and vascular cell adhesion molecule-1 induction by complement: inhibition with anti-human C5 therapy or cGMP analogues. Arterioscler Thromb Vasc Biol. 1999;19:2623–9.
   PubMed Web of Science ®Google Scholar
• Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, . Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000;105:1363–71.
   PubMed Web of Science ®Google Scholar
• Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, . Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 1990;249:146–51.
   PubMed Web of Science ®Google Scholar
• Huang J, Kim LJ, Mealey R, Marsh HC Jr, Zhang Y, Tenner AJ, . Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science. 1999;285:595–9.
   PubMed Web of Science ®Google Scholar
• Ducruet AF, Mocco J, Mack WJ, Coon AL, Marsh HC, Pinsky DJ, . Pre-clinical evaluation of an sLe x-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke. J Med Primatol. 2007;36:375–80.
   PubMedGoogle Scholar
• Zacharowski K, Otto M, Hafner G, Marsh HC Jr, Thiemermann C. Reduction of myocardial infarct size with sCR1sLe(x), an alternatively glycosylated form of human soluble complement receptor type 1 (sCR1), possessing sialyl Lewis x. Br J Pharmacol. 1999;128:945–52.
   Google Scholar
• Fiane AE, Mollnes TE, Videm V, Hovig T, Hogasen K, Mellbye OJ, . Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 1999;6:52–65.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Stahl GL, Pan HL, Rendig SV, Fletcher MP, Longhurst JC. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs. Am J Physiol. 1995;268:H448–57.
   Google Scholar
• Ferraresso M, Macor P, Valente M, Della Barbera M, D'Amelio F, Borghi O, . Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. Transplantation. 2008;86:1445–51.
   Google Scholar
• Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int. 2003;63:134–42.
   PubMed Web of Science ®Google Scholar
• Otto M, Hawlisch H, Monk PN, Muller M, Klos A, Karp CL, . C5a mutants are potent antagonists of the C5a receptor (CD88) and of C5L2: position 69 is the locus that determines agonism or antagonism. J Biol Chem. 2004;279: 142–51.
   PubMed Web of Science ®Google Scholar
• Lewis AG, Kohl G, Ma Q, Devarajan P, Kohl J. Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol. 2008;153: 117–26.
   Google Scholar
• Kim GH, Mocco J, Hahn DK, Kellner CP, Komotar RJ, Ducruet AF, . Protective effect of C5a receptor inhibition after murine reperfused stroke. Neurosurgery. 2008;63: 122–5; discussion 5–6.
   Google Scholar
• Zheng X, Zhang X, Feng B, Sun H, Suzuki M, Ichim T, . Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury. Am J Pathol. 2008;173:973–80.
   PubMed Web of Science ®Google Scholar
• Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, Taylor SM. Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol. 2004; 142:756–64.
   PubMed Web of Science ®Google Scholar
• Ducruet AF, Hassid BG, Mack WJ, Sosunov SA, Otten ML, Fusco DJ, . C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J Cereb Blood Flow Metab. 2008;28: 1048–58.
   Google Scholar
• Sim RB, Tsiftsoglou SA. Proteases of the complement system. Biochem Soc Trans. 2004;32:21–7.
   PubMed Web of Science ®Google Scholar
• Buerke M, Schwertz H, Seitz W, Meyer J, Darius H. Novel small molecule inhibitor of C1s exerts cardioprotective effects in ischemia-reperfusion injury in rabbits. J Immunol. 2001;167:5375–80.
   Google Scholar
• Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, . Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol. 2002; 169:2126–33.
   PubMed Web of Science ®Google Scholar
• Reid RR, Woodcock S, Shimabukuro-Vornhagen A, Austen WG Jr, Kobzik L, Zhang M, . Functional activity of natural antibody is altered in Cr2-deficient mice. J Immunol. 2002;169:5433–40.
   PubMed Web of Science ®Google Scholar
• Williams JP, Pechet TT, Weiser MR, Reid R, Kobzik L, Moore FD Jr, . Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol. 1999;86:938–42.
   PubMed Web of Science ®Google Scholar
• Haas MS, Alicot EM, Schuerpf F, Chiu I, Li J, Moore FD, . Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc Res. 2010;87:618–27.
   Google Scholar
• Strunk R, Colten HR. Inhibition of the enzymatic activity of the first component of complement (C1) by heparin. Clin Immunol Immunopathol. 1976;6:248–55.
   PubMedGoogle Scholar
• Tanhehco EJ, Kilgore KS, Naylor KB, Park JL, Booth EA, Lucchesi BR. Reduction of myocardial infarct size after ischemia and reperfusion by the glycosaminoglycan pentosan polysulfate. J Cardiovasc Pharmacol. 1999;34:153–61.
   PubMed Web of Science ®Google Scholar
• Lauver DA, Booth EA, White AJ, Poradosu E, Lucchesi BR. Sulodexide (KRX-101) attenuates myocardial ischemia/reperfusion injury and the deposition of C-reactive protein in areas of infarction without affecting hemostasis. J Pharmacol Exp Ther. 2005;312:794–800.
   Google Scholar
• Doekes G, van Es LA, Daha MR. C1-inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates. Immunology. 1983;49: 215–22.
   Google Scholar
• Nielsen EW, Waage C, Fure H, Brekke OL, Sfyroera G, Lambris JD, . Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement. Mol Immunol. 2007;44:1819–26.
   PubMed Web of Science ®Google Scholar
• Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med. 2001;194:1609–16.
   PubMed Web of Science ®Google Scholar
• Buerke M, Murohara T, Lefer AM. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion. Circulation. 1995;91:393–402.
   PubMed Web of Science ®Google Scholar
• Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P, . Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation. 1997;95:701–8.
   PubMed Web of Science ®Google Scholar
• Gesuete R, Storini C, Fantin A, Stravalaci M, Zanier ER, Orsini F, . Recombinant C1 inhibitor in brain ischemic injury. Ann Neurol. 2009;66:332–42.
   PubMed Web of Science ®Google Scholar
• Harhausen D, Khojasteh U, Stahel PF, Morgan BP, Nietfeld W, Dirnagl U, . Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. J Neuroinflammation. 2010;7:15–26.
   PubMedGoogle Scholar
• Yamada K, Miwa T, Liu J, Nangaku M, Song WC. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol. 2004;172:3869–75.
   Google Scholar
• Fondevila C, Shen XD, Tsuchihashi S, Uchida Y, Freitas MC, Ke B, . The membrane attack complex (C5b-9) in liver cold ischemia and reperfusion injury. Liver Transpl. 2008;14: 1133–41.
   Google Scholar
• Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–64.
   PubMed Web of Science ®Google Scholar
• Cocchio C, Marzella N. Cinryze, a human plasma-derived C1 esterase inhibitor for prophylaxis of hereditary angioedema. P T. 2009;34:293–328.
   Google Scholar
• Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med. 1998;24: 635–8.
   PubMed Web of Science ®Google Scholar
• de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, . Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J. 2002;23:1670–7.
   PubMed Web of Science ®Google Scholar
• Thielmann M, Marggraf G, Neuhauser M, Forkel J, Herold U, Kamler M, . Administration of C1-esterase inhibitor during emergency coronary artery bypass surgery in acute ST-elevation myocardial infarction. Eur J Cardiothorac Surg. 2006;30:285–93.
   PubMed Web of Science ®Google Scholar
• Horstick G, Berg O, Heimann A, Gotze O, Loos M, Hafner G, . Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation. 2001;104:3125–31.
   PubMed Web of Science ®Google Scholar
• Aerzteschaft Add. Schwerwiegende Thrombenbildung nach Berinert HS. Deutsches Aerzteblatt. 2000;97:1016.
   Google Scholar
• van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest. 1983;71:149–58.
   PubMed Web of Science ®Google Scholar
• Fitch JC, Rollins S, Matis L, Alford B, Aranki S, Collard CD, . Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation. 1999;100: 2499–506.
   PubMed Web of Science ®Google Scholar
• Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG, . Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184–90.
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, . Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003;108:1176–83.
   PubMed Web of Science ®Google Scholar
• Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, . Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2004;77:942–9; discussion 9–50.
   PubMed Web of Science ®Google Scholar
• Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC, . Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial. JAMA. 2004;291:2319–27.
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, . Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007;297:43–51.
   PubMed Web of Science ®Google Scholar
• Testa L, Van Gaal WJ, Bhindi R, Biondi-Zoccai GG, Abbate A, Agostoni P, . Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg. 2008;136:884–93.
   PubMed Web of Science ®Google Scholar
• Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation. 1998;97:2259–67.
   PubMed Web of Science ®Google Scholar
• Lazar HL, Bokesch PM, van Lenta F, Fitzgerald C, Emmett C, Marsh HC Jr, . Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation. 2004; 110(11 Suppl 1):II274–9.
   Google Scholar
• Lazar HL, Keilani T, Fitzgerald CA, Shapira OM, Hunter CT, Shemin RJ, . Beneficial effects of complement inhibition with soluble complement receptor 1 (TP10) during cardiac surgery: is there a gender difference? Circulation. 2007;116 (11 Suppl):I83–8.
   Google Scholar
• Keshavjee S, Davis RD, Zamora MR, de Perrot M, Patterson GA. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg. 2005;129:423–8.
   PubMed Web of Science ®Google Scholar
• Beranek JT. Why did the anti-C5 complement antibody pexelizumab not reduce infarct size but influence clinical outcomes positively when applied as adjunctive therapy to primary percutaneous coronary intervention? Circulation. 2004;109:e195–6; author reply e–6.
   Google Scholar
• Ganote CE. Contraction band necrosis and irreversible myocardial injury. J Mol Cell Cardiol. 1983;15:67–73.
   PubMed Web of Science ®Google Scholar
• Mulligan MS, Warner RL, Rittershaus CW, Thomas LJ, Ryan US, Foreman KE, . Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol. 1999;162:4952–9.
   PubMed Web of Science ®Google Scholar
• Harris CL, Williams AS, Linton SM, Morgan BP. Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-life in vivo. Clin Exp Immunol. 2002;129:198–207.
   PubMed Web of Science ®Google Scholar
• Pratt JR, Jones ME, Dong J, Zhou W, Chowdhury P, Smith RA, . Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant ischemia/ reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol. 2003;163:1457–65.
   PubMedGoogle Scholar
• Smith GP, Smith RA. Membrane-targeted complement inhibitors. Mol Immunol. 2001;38:249–55.
   Google Scholar
• Smith RA, Dodd I, Mossakowska DEI, inventors. Conjugates of soluble peptidic compounds with membrane-binding agents. Switzerland patent US patent WO 98/02454. 1998.
   Google Scholar
• Banz Y, Hess OM, Robson SC, Csizmadia E, Mettler D, Meier P, . Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovasc Res. 2007;76: 482–93.
   Google Scholar
• Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, . Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005;115:2444–53.
   PubMed Web of Science ®Google Scholar
• Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, Song H, . Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006;177:7266–74.
   Google Scholar
• Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/ reperfusion injury. J Immunol. 2008;181:8068–76.
   Google Scholar
• Platt JL, Vercellotti GM, Lindman BJ, Oegema TR Jr, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells. Implications for pathogenesis of hyperacute rejection. J Exp Med. 1990;171:1363–8.
   Google Scholar
• Wuillemin WA, te Velthuis H, Lubbers YT, de Ruig CP, Eldering E, Hack CE. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol. 1997;159:1953–60.
   PubMed Web of Science ®Google Scholar
• Laumonier T, Walpen A, Maurus C, Mohacsi PJ, Matozan K, Korchagina E, . Dextran sulfate acts as an endothelial cell protectant and inhibits human complemen-and NK cell-mediated cytotoxicity against porcine cells. Transplantation. 2003;76:838–43.
   PubMedGoogle Scholar
• Zeerleder S, Mauron T, Lammle B, Wuillemin WA. Effect of low-molecular weight dextran sulfate on coagulation and platelet function tests. Thromb Res. 2002;105: 441–6.
   Google Scholar
• Banz Y, Hess OM, Robson SC, Mettler D, Meier P, Haeberli A, . Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury. Eur Heart J. 2005;26:2334–43.
   PubMedGoogle Scholar
• Banz Y, Rieben R, Zobrist C, Meier P, Shaw S, Lanz J, . Addition of dextran sulfate to blood cardioplegia attenuates reperfusion injury in a porcine model of cardiopulmonary bypass. Eur J Cardiothorac Surg. 2008;34:653–60.
   Google Scholar
• Menger MD, Vollmar B. Pathomechanisms of ischemia-reperfusion injury as the basis for novel preventive strategies: is it time for the introduction of pleiotropic compounds? Transplant Proc. 2007;39:485–8.
   Google Scholar
• Mason JC, Ahmed Z, Mankoff R, Lidington EA, Ahmad S, Bhatia V, . Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res. 2002;91:696–703.
   PubMed Web of Science ®Google Scholar
• Viedt C, Shen W, Fei J, Kamimura M, Hansch GM, Katus HA, . HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9. Basic Res Cardiol. 2003;98:353–61.
   Google Scholar
• Rutkowski MJ, Sughrue ME, Kane AJ, Ahn BJ, Fang S, Parsa AT. The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res. 2010;59:897–905.
   PubMed Web of Science ®Google Scholar
• Pekny M, Wilhelmsson U, Bogestal YR, Pekna M. The role of astrocytes and complement system in neural plasticity. Int Rev Neurobiol. 2007;82:95–111.
   PubMed Web of Science ®Google Scholar
• He S, Atkinson C, Qiao F, Cianflone K, Chen X, Tomlinson S. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009;119:2304–16.
   Google Scholar